Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
20.46
-0.59 (-2.80%)
Jan 31, 2025, 4:00 PM EST - Market closed
Travere Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for TVTX stock have an average target of 26.18, with a low estimate of 19 and a high estimate of 41. The average target predicts an increase of 27.96% from the current stock price of 20.46.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TVTX stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 4 | 4 | 4 | 4 |
| Buy | 4 | 3 | 6 | 6 | 6 | 6 |
| Hold | 6 | 4 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 12 | 13 | 13 | 13 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $22 | Strong Buy | Maintains | $18 → $22 | +7.53% | Jan 15, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $12 → $22 | Hold | Maintains | $12 → $22 | +7.53% | Nov 14, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $23 → $27 | Buy | Maintains | $23 → $27 | +31.96% | Nov 1, 2024 |
| Barclays | Barclays | Buy Maintains $18 → $20 | Buy | Maintains | $18 → $20 | -2.25% | Nov 1, 2024 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $9 → $27 | Hold → Buy | Upgrades | $9 → $27 | +31.96% | Oct 21, 2024 |
Financial Forecast
Revenue This Year
235.83M
from 145.24M
Increased by 62.37%
Revenue Next Year
381.43M
from 235.83M
Increased by 61.74%
EPS This Year
-3.71
from -1.50
EPS Next Year
-1.17
from -3.71
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 257.6M | 567.3M | 778.6M | |||
| Avg | 235.8M | 381.4M | 556.4M | |||
| Low | 217.6M | 263.8M | 364.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 77.3% | 140.5% | 104.1% | |||
| Avg | 62.4% | 61.7% | 45.9% | |||
| Low | 49.8% | 11.8% | -4.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.25 | 0.91 | 2.85 | |||
| Avg | -3.71 | -1.17 | 0.63 | |||
| Low | -4.02 | -2.15 | -0.66 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.